Skip to main content
SpringerLink
Log in

Biological drugs safe for severe psoriasis in children

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Zitouni J, et al. Effectiveness and Safety of Adalimumab, Etanercept and Ustekinumab for Severe Psoriasis in Children Under 12 Years of Age: A French-Italian Daily Practice Cohort (BiPe Jr) Pediatric Drugs : 13 Apr 2022. Available from: URL: https://doi.org/10.1007/s40272-022-00501-6

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Biological drugs safe for severe psoriasis in children. Reactions Weekly 1903, 12 (2022). https://doi.org/10.1007/s40278-022-13574-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-022-13574-0

Search

Navigation